Prolonged treatment with human parathyroid hormone (hPTH) in rats results in development of bone tumors, though this finding has not been supported by clinical experience. The PTH type 1 receptor agonist abaloparatide, selected for its bone anabolic activity, is under clinical development to treat postmenopausal women with osteoporosis. To determine the carcinogenic potential of abaloparatide, Fischer (F344) rats were administered SC daily abaloparatide at doses of 0, 10, 25, and 50 mg/kg or 30 mg/kg hPTH(1e34) as a positive control for up to 2 years. Robust increases in bone density were achieved at all abaloparatide doses and with hPTH(1e34). Comprehensive histopathological analysis reflected a comparable continuum of proliferative changes in bone, mostly osteosarcoma, in both abaloparatide and hPTH(1e34) treated rats. Comparing the effects of abaloparatide and hPTH (1e34) at the 25 and 30 mg/kg respective doses, representing similar exposure multiples to the human therapeutic doses, revealed similar osteosarcoma-associated mortality, tumor incidence, age at first occurrence, and metastatic potential. There were no increases in the incidence of non-bone tumors with abaloparatide compared to vehicle. Thus, near life-long treatment with abaloparatide in rats resulted in dose and time dependent formation of osteosarcomas, with a comparable response to hPTH(1e34) at similar exposure.
Introduction
Abaloparatide is a synthetic agonist of the parathyroid hormone type 1 receptor (PTH1R) and bone anabolic agent that is currently under development for the treatment of postmenopausal osteoporosis (PMO). When injected subcutaneously (SC), abaloparatide increases bone formation with lesser effects on bone resorption, resulting in increased bone mass in animals (Bahar et al., 2016) and in humans (Leder et al., 2015) . Recent evidence has demonstrated that abaloparatide reduced both vertebral and nonvertebral fractures in PMO patients after 18 months of daily SC administration (Miller et al., 2016) .
Abaloparatide was originally selected for its bone anabolic activity and more limited effect on bone resorption and calcium mobilization relative to hPTH(1e34). With 41% homology to PTH(1e34) and 76% homology to PTHrP(1e34), its greater homology to PTHrP reflects the ability of PTHrP to increase bone formation with less stimulation of bone resorption and hypercalcemia (Horwitz et al., 2003) . These differential actions are mediated by distinct PTH1R conformation selectivity, with PTHrP binding with greater selectivity to the RG conformation (relative to R0) than PTH (Hattersley et al., 2016) . Efficient binding to R0 results in prolonged signaling responses in cells and prolonged calcemic responses, whereas selective binding to RG results in more transient responses (Ferrandon et al., 2009) . Abaloparatide binds with greater selectivity to the RG conformation than does hPTH(1e34) or hPTHrP, and as a result of this RG bias, abaloparatide mediates more transient cAMP responses in PTH1R-expressing cells (Hattersley et al., 2016) . These findings provide a mechanistic basis e i.e., transient intracellular signaling via RG-selective binding e that can account for the favorable anabolic effects that abaloparatide has demonstrated in preclinical and clinical studies. Two recombinant human PTH peptides have been approved for the treatment of PMO. Teriparatide, or rhPTH(1e34) , is the Based on their stimulatory effects on osteoblasts, chronic 2-year studies were performed in rats to determine their potential impact on carcinogenicity. These studies demonstrated dose and duration-related osteosarcomas with rhPTH(1e34) (Vahle et al., 2002 (Vahle et al., , 2004 and rhPTH(1e84) (Jolette et al., 2006) in F344 rats. Despite these observations, an increased incidence of osteosarcomas has not been linked to the clinical use of either approved PTH product (Andrews et al., 2012; Cipriani et al., 2012; Krohn et al., 2016) , though the duration of use has been limited to 2 years.
Based on its bone-anabolic action through agonism of the PTH1R, the carcinogenic potential of abaloparatide was examined in a 2-year study in F344 rats that followed the study design guidelines of the Committee for Medicinal Products for Human Use (CHMP) and OECD Guideline 417, and was reviewed by relevant regulatory agencies. In addition to the 3 dose levels of daily abaloparatide tested, a group of rats dosed with hPTH(1e34) at the mid-dose tested in the Vahle et al., 2004 paper (Vahle et al., 2004 was also included as a positive control group.
Methods

Study design
Male and female F344 rats were obtained from Charles River, St Constant, Quebec at 4e5 weeks of age and were acclimated for 3 weeks prior to initiation of treatment. Rats were housed individually in stainless steel cages prior to randomization, and group housed thereafter (up to 3 sex and group matched rats per cage) except during designated study procedures. Certified pelleted commercial laboratory diet, Rodent Chow 5CR4 (PMI Feeds, Inc. St Louis, MO) and municipal tap water (purified by reverse osmosis and ultraviolet irradiation) were provided ad libitum except during designated study procedures. This study was conducted at Charles River Laboratories Preclinical Services, Montreal in accordance with American Association of Laboratory Animal Care and Canadian Association of Laboratory Animal Care guidelines, was approved by Charles River Laboratories' Institutional Animal Care and Use Committee, and was conducted in compliance with the Good Laboratory Practice Regulations of the Food and Drug Administration (21 CFR Part 58).
Rats were randomly assigned to 5 treatment groups per sex (n ¼ 60/group), stratified to body weight to ensure similar means across groups. Groups were administered abaloparatide at daily subcutaneous doses of 0, 10, 25, and 50 mg/kg; a separate group received 30 mg/kg hPTH(1e34) as a positive control. The abaloparatide doses of 10, 25, and 50 mg/kg were estimated to result in 3, 11 and 22-fold greater exposure than the 80 mg dose used in humans based on area-under-the-curve (AUC) predictions; the 30 mg/kg hPTH(1e34) dose used was approximately 14-to 25-fold higher than the 20 mg dose of teriparatide (FDA, 2002) . SC injections (1 ml/kg body weight) were administered approximately the same time each day for 7 days a week, with injection sites rotated daily between 7 areas in the dorsal region.
Rats were observed twice daily for mortality and signs of ill health, with a detailed physical examination and food consumption and body weight recorded performed every week. From Week 26 onwards, all rats were also examined weekly for the presence of palpable masses. The site, size, and appearance of these masses were recorded when first detected and, following this initial description, their progression was monitored. Whole body radiography was performed on scheduled and unscheduled necropsies to detect abnormalities in the skeleton and alterations in soft tissue radiodensity to direct trimming of additional tissues for histopathology. When the number of surviving animals in any treatment group reached 20, test article was discontinued.
At necropsy, a full panel of tissues were collected and examined by histopathology, including the distal femur, proximal tibia, sternum, and lumbar vertebrae (L5-L6). In addition, all abnormalities detected by macroscopic and radiologic evaluation were subject to further microscopic evaluation. Except for those tissues with identified abnormalities, the right femur (including subregions) and the lumbar spine (L1-L4) were subjected to dual-energy x-ray analysis (DXA) ex vivo using a Hologic Discovery A scanner to quantify the pharmacodynamic response after up to 2 years of treatment.
Toxicokinetic (TK) and anti-therapeutic antibody analysis
Blood samples were collected from separate groups of animals dosed with 0, 10, 25, or 50 mg/kg abaloparatide or 30 mg/kg hPTH(1e34) SC daily (n ¼ 12/sex/group) to capture drug exposure at 7 timepoints during the first 3 h after injection after 1, 26, and 52 weeks of dosing. Blood was obtained by jugular venipuncture without anesthesia, and the resulting plasma samples were analyzed for concentration of abaloparatide by radioimmunoassay at PPD Inc (ICDIM275.1 V3.00, Richmond, VA). hPTH(1e34) concentration was measured using a validated ELISA to confirm appropriate dosing. Pharmacokinetic parameters were estimated for the abaloparatide groups using WinNonlin pharmacokinetic software (Pharsight Corp., Mountain View, California). A non-compartmental approach consistent with the subcutaneous route of administration was used for parameter The presence of anti-abaloparatide antibodies were assessed in serum samples collected prior to treatment and prior to termination for TK animals (week 52) and main study animals by radioimmunoassay at PPD Inc. Anti-drug antibodies were not assessed in the hPTH(1e34) positive control group.
Statistics
All statistical analyses were performed using SAS (version 8.2; SAS Institute, Cary, NC). The survival function of each group was estimated using the Kaplan-Meier product-limit method applied on daily intervals. For the males' and females' datasets, the significance of group effects on mortality rates was determined among the Vehicle and abaloparatide groups. Group homogeneity was first determined by a Logrank test, with significant heterogeneity resulting in implementation of a Peto's two-sided test and examination of a dose-response relationship. Significance was determined based on p 0.05.
For the incidence tumor data, neoplastic lesions categorized as palpable were analyzed in a mortality-independent context according to Peto's onset rate method (Peto et al., 1980) . Tumors categorized as nonpalpable were analyzed using the mortalitydependent method. In this context, each neoplastic finding was classified as the cause of death (fatal) or not the cause of death (incidental) and was analyzed accordingly using Peto's death rate and the prevalence methods, as per the US FDA's Guidance for Industry (FDA, 2001) . The processing of incidental tumors was done by creating a single separate interval for the time period following the experimental period (terminal sacrifice period) and by dividing the experimental period into fixed intervals.
For the DXA data, the vehicle and abaloparatide groups were analyzed by one way analysis of variance (ANOVA). If the group variances were homogenous (p > 0.05 by Levene's test), group differences from vehicle controls were determined by Dunnett's post-test, otherwise they were determined by Dunn's test. Differences between the vehicle and hPTH(1e34) group were determined by two-sample t-test, or a Wilcoxon-rank-sum test if group variances were significantly different (p 0.05 by Levene's test).
Results
Drug exposure
Peak abaloparatide concentrations were generally observed between 0.25 and 0.5 h postdose, with half-life (t 1/2 ) estimated to be between 0.221 and 0.631 h. There were no noteworthy differences in exposure between genders, thus the data were combined for modeling purposes. Exposure generally increased with dose level, with greater than dose proportionally at Weeks 26 and 52 when some dose accumulation was evident (Table 1) . The week 52 toxicokinetic data from this carcinogenicity study and pharmacokinetic data from a human Phase 1 study after 7 days of dosing was used to determine the relative differences in abaloparatide exposure. Based on the AUC data from female rats at week 52 and from postmenopausal women administered abaloparatide at 80 mg SC once daily for 7 days, the exposure multiples in this study were approximately 4-, 16-and 28-fold at the 10, 25 and 50 mg/kg dose levels respectively. Anti-abaloparatide antibodies were seen in one female at 25 mg/kg and 2 females at 50 mg/kg at Week 52 (TK) and in 2 main study females at 50 mg/kg prior to termination.
Mortality
Male rats treated with abaloparatide at 25 mg/kg and hPTH(1e34) at 30 mg/kg had a significant increase in mortality rate relative to Vehicle and were terminated early at weeks 97, 88 and 99, respectively when the number of survivors reached 15/group (Table 2 ). All female groups were euthanized at week 104, though a significant increase in mortality rate was observed in the 50 mg/kg abaloparatide group. These differences in mortality rate were attributed to osteosarcomas, which were more prevalent in males than females irrespective of the compound administered. Notably, mortalities secondary to osteosarcoma did not differ in rats treated with 25 mg/kg abaloparatide when compared to rats treated with 30 mg/kg hPTH(1e34). Fatal osteosarcomas were first observed in abaloparatide-treated male rats on Day 310 and in female rats on Day 398, and with hPTH(1e34) on Days 343 and 419 in male and females respectively.
Bone radiodensity and mass
Increased radio-opacity was observed throughout the skeleton in nearly all animals treated with abaloparatide and hPTH(1e34), as illustrated for abaloparatide in Fig. 1 . These changes corresponded to significant increases in bone mineral content (BMC) by DXA at the lumbar spine and whole femur (Fig. 1) . Lumbar spine BMC was increased þ61, þ66, and 80% relative to vehicle controls for males at 10, 25, and 50 mg/kg, respectively, and þ58, þ92, and 93% for females. Increases in BMC in the 25 and 50 mg/kg abaloparatide groups were generally comparable to the changes in the 30 mg/kg hPTH (1e34) group. At the femur, the abaloparatide-and hPTH(1e34)-mediated changes in whole femur BMC were due to similar increases at both cortical (femur diaphysis) and mixed trabecular/cortical (distal femur) sites. Other local radiological changes, either characterized by bone loss, bone production or mixed reaction (mixture of bone production and bone loss), were common observations in given abaloparatide or hPTH(1e34). Localized radiographic bone loss was observed at a number of skeletal sites, including the lumbar spine, sternum and tibia, in both male and female rats treated with abaloparatide at all dose levels, or hPTH(1e34), but rarely in vehicle control rats. Localized radiographic mineralization in soft tissues, predominantly in the lungs and abdominal organs, was a common change in rats administered abaloparatide or hPTH(1e34). This dose-dependent effect was more predominant in males than in females, and the histopathology of these changes are further described below.
Neoplastic finding in bone
Abaloparatide-related proliferative findings in bones included osteosarcoma with lesser frequency benign osteoblastoma and focal osteoblast hyperplasia, as summarized in Table 3 . This continuum of effects on the osteoblast lineage was dose-dependent and present in both males and females administered 10 mg/kg abaloparatide. Similar proliferative changes were observed in hPTH(1e34)-treated rats at 30 mg/kg, with incidences similar to those observed with abaloparatide at 25 mg/kg. In contrast, bone neoplasia was uncommon in vehicle control rats with a single occurrence of osteosarcoma in males (tibia) and females (femur).
Osteosarcoma arose from various skeletal locations in abaloparatide-treated rats; the tibia was the most frequently affected single bone. Involvement of the forelimbs compared to the pelvic limbs was less common. Osteosarcoma was also frequently seen in the axial skeleton, mostly in the thoracic and lumbar spine. The neoplasm frequently impinged upon the spinal cord when located in the vertebral column (seen histologically in Fig. 2A) , which provided an explanation for the hindlimb paralysis noted in some animals treated with abaloparatide or hPTH(1e34). Bones of the extremities (tail, feet, and skull) were generally spared by the neoplastic process. Overall, males were more susceptible to osteosarcoma development than females when treated with abaloparatide or hPTH(1e34). These neoplasms were often correlated with localized radiographic changes characterized by bone loss, bone production or mixed reaction, and/or masses found in bones at necropsy (Fig. 1) .
Osteosarcomas were commonly multicentric, originating from different bones, and metastases to soft tissues were frequent and sometimes widespread to the lung, liver, spleen, adrenal gland, and kidney. These metastases often correlated with radiographic mineralization noted in lung and abdominal organs and, at necropsy, with masses and/or nodules in the lung, liver and spleen. The microscopic appearance of the osteosarcomas were highly variable as previously reported with hPTH(1e34) (Vahle et al., 2002) . The predominant histological types were the osteoplastic, osteoblastic and fibroblastic subtypes with a small number of telangiectatic osteosarcoma (Fig. 2) . The compound subtype, combining bone and cartilaginous tumoral matrix, was rarely seen (Fig. 2E) . The marked variation in amount of tumor bone between subtypes explains the radiological variability between osteosarcoma, which ranged from an osteolytic (bone loss) response to bone production.
In rats, osteoblastoma represents a benign neoplastic entity that has specifically been associated with chronic administration of rhPTH(1e34) or rhPTH(1e84) (Jolette et al., 2006; Vahle et al., 2002 Vahle et al., , 2004 . Such neoplasm is characterized by an expansile endosteal and/or cortical growth that does not breach the periosteal surface, minimal invasion at the tumor margins and minimal cellular atypia and it is often associated with localized radiographic bone loss. Osteoblastoma was seen in various bones of abaloparatide-treated males and females at 10 mg/kg/day and most commonly affected the tibia; this tumor was also found in several hPTH (1e34)-treated males and females.
Other neoplastic findings
There were no other meaningful differences in the incidence of other neoplasms among male and female groups treated either with abaloparatide or hPTH(1e34). These neoplasms were those typically encountered in aging F344 rats and were randomly distributed among groups with no dose-related pattern identified (Table 4 ). The most commonly observed spontaneous tumors included interstitial (Leydig) cell adenoma in the testis, adenoma of the pars distalis in the pituitary gland (both sexes), large granular lymphocytic (LGL) leukemia (both sexes), benign pheochromocytoma in the adrenal gland (primarily in males), fibroadenoma in the mammary gland (primarily in females), endometrial stromal polyp in the uterus and C-cell adenoma in the thyroid gland (both sexes). Although the overall incidence of LGL leukemia was lower in males treated with abaloparatide and hPTH(1e34), this was likely related to the increased mortality in those groups.
Non-neoplastic findings in bone
Focal osteoblast hyperplasia (FOH) has been described as part of the morphologic continuum associated with chronic administration of rhPTH (1e34) or rhPTH (1e84) to the rat (Jolette et al., 2006; Vahle et al., 2002) . This non-neoplastic finding was observed in abaloparatide-treated males and females with an increased b Male groups treated with ABL at 25 mg/kg, abaloparatide at 50 mg/kg and hPTH(1e34) at 30 mg/kg were terminated at weeks 97, 88 and 99, respectively when number of survivors reached 15/group. c One originally identified male was found to be a female pseudohermaphrodite at necropsy; it was reassigned to its true sex. Note in 1B the bilateral increased bone radiopacity in both axial and appendicular bones as well as several sites of localized bone production; radius (arrow), thoracic spine (*) and lung (arrowheads) confirmed histologically to be multicentric osteosarcoma with pulmonary metastasis. DXA BMC was measured ex vivo at the (C) lumbar spine (L1-L4) and (D) whole right femur, as well as in (E) diaphyseal and (F) distal regions of the femur. Mean ± SD, *p < 0.05 vs Veh within each sex. incidence in males at 25 mg/kg/day, and in females at 10 mg/kg/ day (see Fig. 3 ). FOH was also noted in some males and females administered hPTH (1e34). The tibia, lumbar vertebra and femur were the most frequent sites affected with FOH.
Endosteal hyperostosis was a very common and systemic skeletal effect in abaloparatide-treated groups at 10 mg/kg/day (dosedependent based on severity; data not shown) and in the hPTH (1e34)-treated groups. This change was characterized by trabecular hypertrophy, sometimes associated with peritrabecular fibrosis and/or woven bone deposition. The distribution was usually diffuse within the endosteal bone compartment and involved the epiphysis, metaphysis and diaphysis. Hyperostosis was seen at low incidence in the vehicle treated-rats, predominantly in the female subset; these observations were consistent with the reported spontaneous occurrence of this diagnostic entity in the aging F344 strain (Thurman and Bucci, 1994) . Osteofibrous dysplasia was another observed treatment-related effect in abaloparatide-and hPTH(1e34)-treated groups (Table 3) . This microscopic change was scattered in various bones and sometimes correlated with focal radiographic bone loss. The incidence of this change was dose-dependent, with a similar number of observations across the 25 mg/kg abaloparatide and 30 mg/kg hPTH(1e34) groups in males (6) and females (10). Such lesion has been described in rhPTH(1e84)-treated rats (Jolette et al., 2006) and bears similarity with the focal stromal proliferation described by Vahle (Vahle et al., 2004) in bones of rats administered rhPTH(1e34). Osteofibrous dysplasia was characterized by replacement of the marrow and trabecular bone by well differentiated spindled cellular elements in a collagenous matrix admixed with predominantly woven small bone trabeculae lined with an osteoblastic rim. The fibroblastic and osteoblastic cells of this lesion lacked the cellular atypia present in their malignant counterparts.
Non-neoplastic/non-bone observations
Microscopic changes that occurred in both the abaloparatide and hPTH(1e34) treatment groups included effects on the large arteries, kidney, lung, spleen, and urinary bladder as reported in Table 5 . These changes generally occurred at similar incidences across the 25 mg/kg abaloparatide and 30 mg/kg hPTH(1e34) groups. Medial mineralization, generally graded minimal to slight in severity with a multifocal distribution, involving the aortic arch and/or, less commonly, the pulmonary artery was commonly seen in animals treated with abaloparatide or hPTH(1e34). A dose response was not evident in either sex and males were more commonly affected than females. The change did not extend to other blood vessels including the routinely examined thoracic aorta. In the kidney, increased mineral localized in the pelvis was commonly observed in male and female rats given abaloparatide or hPTH(1e34). The incidence of this change was dose-dependent, with females were more commonly affected than males. The mineral deposits were generally graded minimal in severity and consisted in multifocal basophilic granular to finely spicular material found free in the pelvic recess or trapped within or under the urothelium. Increased extramedullary hematopoiesis in the spleen was noted at a greater incidence in animals treated with abaloparatide or hPTH(1e34) ( Table 5) , consistent with the marked reductions in marrow space observed histologically (as shown at the distal femur in Fig. 4 ) and secondary displacement of hematopoiesis. Dilatation, hemorrhage and/or inflammation of the urinary bladder were observed at a slightly increased incidence in abaloparatide and hPTH(1e34)-treated male rats. These observations were considered to be secondary, at least in some affected rats, to the presence of a malignant bone tumor localized in the spine or pelvis, which may have interfered with the neural control of micturition. Alveolar histiocytosis in the lung was slightly increased in incidence in males and females administered abaloparatide or hPTH(1e34). These changes were generally minimal in severity and multifocal and subpleural in distribution and may have occurred as a consequence to the frequent metastasis of osteosarcoma found in the lung.
Discussion
This study investigated the effects of near-lifetime exposure to the PTH1R agonist abaloparatide in F344 rats, comparing them to a 30 mg/kg dose of hPTH(1e34) which has previously been shown to induce osteosarcoma. Similar to hPTH(1e34), chronic daily abaloparatide administration resulted in a dose-dependent increase in the incidence of osteosarcoma and associated mortality. These effects occurred along with marked increases in bone mass, with increased osteosarcoma evident at the lowest tested dose (10 mg/ kg), representing an approximate 4-fold exposure multiple of the clinical dose. The incidence of neoplastic changes between abaloparatide and hPTH(1e34) at comparable exposure multiples (25 versus 30 mg/kg) were quite similar. Although these and other proliferative changes were observed in bone, abaloparatide did not increase the incidence of neoplastic changes in other tissues of the aged rat relative to vehicle or hPTH(1e34) treatment.
To date, an increased incidence of osteosarcoma has not been linked to the clinical use of either rhPTH(1e34) or rhPTH(1e84) (Andrews et al., 2012; Cipriani et al., 2012; Krohn et al., 2016) , perhaps due to the differences in dosing (timing, duration, or level) or species (sensitivity to PTH1R agonists, modes of action in bone) between humans and rats. These chronic rat studies initiate PTH1R agonist administration during a phase of rapid longitudinal skeletal growth and are dosed for nearly their entire lifespan (Tashjian and Chabner, 2002) . In contrast, PTH administration in postmenopausal women is initiated in an aged skeleton for only up to 2 years (2.5% of an 80 year lifespan). Rodents and primates, including humans, differ in their physiology and pharmacology of bone tissue. In addition to differences in intracortical remodeling (near-absent in rats), rodents have an exaggerated anabolic response to PTH and PTHrP, and can tolerate much higher doses. The lowest doses at which rhPTH(1e34) (Vahle et al., 2002) and abaloparatide were tested in the 2-year rat model provided greater 3e4-fold greater exposure than the dose levels administered in humans. At these 'low' doses of hPTH(1e34) and abaloparatide, BMC was increased at the lumbar spine by approximately 50e60%, well above the observed changes over an 18-month period in postmenopausal Arteries affected were the aortic arch and, less often, pulmonary artery within the section of the heart. Fig. 4 . Histologic increases in bone in the distal femur of abaloparatide-treated rats. Dose dependent increases in endosteal bone were evident in representative sagittal sections from the abaloparatide groups and 30 mg/kg PTH group relative to vehicle controls. H&E.
women treated with rhPTH(1e34) (Neer et al., 2001) or abaloparatide (Miller et al., 2016) . In addition to the current lack of observed clinical association between intermittent PTH administration and osteosarcoma to date despite ongoing pharmacovigilance (Andrews et al., 2012; Cipriani et al., 2012; Krohn et al., 2016) , there are several clinical conditions that exhibit elevated PTH or PTHrP that have not shown an association with osteosarcoma. Patients with primary and secondary hyperparathyroidism did not have an increased incidence of osteosarcoma in the Swedish Cancer Registry database, nor did patients with activating mutations of PTH1R (eg. Jansen's metaphyseal chondrodysplasia) (Tashjian and Chabner, 2002) . To date, extended administration of rhPTH(1e34) or rhPTH(1e84) has not resulted in any reported osteosarcomas in patients with hypoparathyroidism, including children (Rubin et al., 2016; Theman et al., 2009; Winer et al., 2010) . High levels of PTHrP have not been associated with increased incidence of osteosarcomas in patients with hypercalcemia of malignancy (Jibrin et al., 2006) .
One theoretical concern regarding abaloparatide was based on its similarity to PTHrP, which was originally purified from multiple cancer cell lines and has been hypothesized to act in a paracrine fashion to mediate local resorption and facilitate tumor growth and metastasis (McCauley and Martin, 2012) . However, some studies using human tissue have suggested that PTHrP positive tumors may exhibit reduced metastatic potential (Henderson et al., 2001 (Henderson et al., , 2006 , an effect distinct from its bone resorbing action. Conflicting evidence has been reported in mouse tumor models, with PTHrP expression both positively (Li et al., 2011) and negatively (Fleming et al., 2009 ) associated with initiation and progression of primary tumors. Although abaloparatide is distinct from both human PTHrP and hPTH(1e34), the data across published carcinogenicity studies indicate that chronic PTH1R agonism does not result in an increased incidence in tumors other than those originating from the osteoblast lineage.
In this study, a higher incidence of osteosarcoma and osteoblastoma was noted in the hPTH(1e34) treated groups when compared to the previous rat carcinogenicity studies evaluating the same 30 mg/kg dose of rhPTH(1e34) (Vahle et al., 2002) . The use of radiographic evaluation of the entire skeleton to identify small tumors conducted in this study, (but not the prior studies with rhPTH(1e34)) likely increased the ability to detect small tumors and may explain the overall increased incidence in this study. Consistent with previous PTH rat carcinogenicity studies, osteosarcoma occurred at a higher rate in males than in females at similar dose levels of abaloparatide and hPTH(1e34). Drug concentrations were similar across sexes, and the cause of the increased osteosarcoma sensitivity in male rats remains unknown.
The non-neoplastic observations in this study including effects on the large arteries, kidney, lung, spleen, and urinary bladder have generally been reported in previous carcinogenicity studies with rhPTH(1e34) (FDA, 2002) and rhPTH(1e84) (Jolette et al., 2006) . Although observations such as extramedullary hematopoiesis were clearly secondary to the changes in bone, the etiology of the other changes including soft tissue mineralization were less clear. These changes represent a class effect which was dose-dependent, with similar incidences, severity, and tissue distribution between the abaloparatide and hPTH(1e34) groups at similar exposures.
Conclusion
The current study demonstrated an increased incidence of osteosarcoma in rats treated chronically with abaloparatide, consistent with previous studies with rhPTH(1e34). These changes were consistent across comparable doses of abaloparatide and hPTH(1e34), with histopathology reflecting similarities in both neoplastic and non-neoplastic observations. Although the clinical translation of the increased rate of osteosarcoma with PTH1R agonists in rats remains unclear, these results suggest that are no additional neoplastic risks associated with near-lifetime exposure to abaloparatide.
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